Is Prescription Drug Pricing The Cure For Partisanship?

Published date26 July 2019
Subject MatterOutpatient Services,Conflicts of Interest,Medicaid,Health Insurance,Ambulatory Surgery Centers,Pharmaceutical Industry,Medicare,Public Disclosure,Prescription Drugs,Rebates,Managed Care Contracts,Risk-Sharing,Physician Fee Schedule,Pharmacy Benefit Manager (PBM),Congressional Budget Office,Price Transparency,Manufacturers,Hospitals,Drug Pricing,Prescription Drug Coverage,Medicare Part D
AuthorErica Kraus,Christine Clements,Theresa Thompson,Susan Ingargiola,Bevin Newman
Law FirmSheppard Mullin Richter & Hampton LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT